Semaglutide Dosing for Weight Loss

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide for weight loss typically follows a stepwise dosing schedule: starting at 0.25 mg weekly and increasing in 0.25 mg increments every 4 weeks until reaching 2.4 mg maintenance. Clinical trials demonstrate meaningful weight reduction at higher doses, though individual response varies significantly based on metabolic factors, adherence, and lifestyle integration.

Understanding semaglutide dosing goes beyond the standard protocol. Genetic predispositions, baseline metabolic markers, and prior medication history all contribute to how your body may respond. PlexusDx supports precision-wellness by helping you and your provider evaluate whether compounded semaglutide, alternative formulations, or complementary peptide protocols align with your individual profile and treatment goals.

Semaglutide Dose Escalation: Standard Protocol and Clinical Rationale

The FDA-approved semaglutide dosing schedule uses gradual escalation to minimize gastrointestinal side effects and allow metabolic adaptation. Weeks 1-4 begin at 0.25 mg; weeks 5-8 increase to 0.5 mg; weeks 9-12 move to 1.0 mg; weeks 13-16 reach 1.7 mg; weeks 17+ maintain 2.4 mg. Each dose targets progressively stronger GLP-1 receptor activation.

Clinical evidence shows most weight loss occurs in the latter dose tiers. The STEP trials demonstrated 15-18% body weight reduction at 2.4 mg versus 8-10% at lower maintenance doses. However, some patients achieve adequate glycemic control and weight reduction at 1.7 mg. Your provider may adjust escalation timing or maintenance dose based on tolerability, efficacy markers, and individual health circumstances.

Factors Influencing Individual Dosing Response: A Clinical Framework

Dosing response varies because semaglutide's efficacy depends on multiple interconnected systems: GLP-1 receptor density, insulin secretion patterns, gastric emptying rate, and appetite regulation pathways. This framework outlines clinical and genetic factors your provider evaluates when personalizing your treatment plan.

Factor Category	Clinical Relevance to Dosing
GLP-1 Receptor Genetics	Variants in GLP1R (rs6923761) may influence receptor sensitivity and titration tolerance; predisposition context supports provider discussion.
Metabolic Baseline	Higher baseline insulin resistance or HbA1c may require slower escalation; fasting glucose and HOMA-IR inform dose timing.
Gastrointestinal Tolerance	Nausea severity at 0.5-1.0 mg may indicate need for extended plateau or dose reduction; some continue at 1.7 mg maintenance successfully.
Body Composition and BMI	Individuals with BMI >40 or significant visceral adiposity may tolerate and benefit from 2.4 mg; lower BMI may plateau at 1.7 mg.
Medication History	Prior GLP-1 use, metformin tolerance, or incretin inhibitor response may predict semaglutide titration patterns and maintenance needs.

Dose Adjustment and Maintenance: Beyond Standard Escalation

Not all patients require 2.4 mg. Clinical practice shows effective weight loss maintenance at 1.7 mg, 1.0 mg, or even microdose protocols for some individuals. Dose reductions may become necessary if side effects persist, or if weight loss plateaus and benefit-to-burden ratio shifts unfavorably. Regular reassessment at 8-12 week intervals guides these decisions.

Some patients benefit from intermittent dosing, extended intervals between injections, or compounded formulations offering flexible dosing between standard increments. Your provider may recommend stepping down once target weight approaches, or pausing to assess weight stability. The goal is identifying the minimum effective dose that sustains results with acceptable tolerability.

Safety, Eligibility, and When Semaglutide May Not Be Appropriate

Semaglutide is not recommended for individuals with personal or family history of medullary thyroid carcinoma, history of pancreatitis, severe renal impairment, or active diabetic retinopathy. Pregnancy and breastfeeding require discontinuation. GI conditions like gastroparesis may limit tolerance. A qualified healthcare provider must evaluate your medical history before starting any GLP-1 therapy.

Common side effects—nausea, vomiting, constipation—typically resolve within weeks but can influence dose tolerance. Dehydration risk increases at higher doses; adequate fluid intake is essential. Rare but serious risks include acute kidney injury and gallbladder complications. Your provider will monitor renal function, inflammatory markers, and gastrointestinal symptoms throughout treatment. Compounded semaglutide from licensed 503A pharmacies follows the same safety monitoring as branded formulations.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP-1 receptor pathways (GLP1R rs6923761) and metabolic genes (FTO rs9939609, MC4R rs17782313) that may help provide context for how your body regulates appetite, glucose homeostasis, and weight distribution. These predispositions are interpreted with a qualified healthcare provider to inform whether standard semaglutide dosing, alternative peptide formulations, or combination protocols may align better with your individual biology.

The genetic test reveals predispositions in peptide signaling pathways, not exact medication response. A favorable GLP-1R variant may suggest potentially better receptor sensitivity, while FTO or MC4R variants may indicate metabolic resilience factors. These insights should be interpreted with your provider as one component of a comprehensive evaluation that also includes metabolic labs (fasting glucose, insulin, lipids), BMI, comorbidities, and prior medication experience.

Combining genetic context with clinical dosing evidence empowers a more informed conversation between you and your provider. Rather than assuming standard protocols work for everyone, understanding your individual predispositions and metabolic baseline can support tailored decisions about escalation pace, maintenance dose, formulation type (compounded versus branded), and whether combination approaches like GLP-Squared dual compound may warrant exploration.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the typical starting dose of semaglutide for weight loss, and how fast does it escalate?

Starting dose is 0.25 mg weekly for weeks 1-4, increasing by 0.25 mg every 4 weeks until reaching 2.4 mg maintenance at week 17+. Some patients plateau at 1.7 mg with adequate results. Escalation timing depends on tolerability and provider oversight.

Does everyone need to reach the 2.4 mg dose, or can lower doses be effective?

Clinical trials show dose-dependent weight loss, but many patients achieve meaningful reduction at 1.7 mg or lower. Your provider may recommend stopping escalation if benefits plateau or side effects outweigh advantages. The minimum effective dose varies individually.

How does PlexusDx help with semaglutide dosing decisions?

PlexusDx compounded semaglutide ($149/mo) offers flexible dosing and the Precision Peptide Genetic Test ($99 add-on or $298 standalone) reveals GLP-1 pathway predispositions, enabling provider conversations about personalized protocols, escalation pace, and alternative formulations.

What happens if I experience severe nausea at my current semaglutide dose?

Nausea typically resolves within 1-2 weeks. If persistent, your provider may extend the plateau at your current dose, reduce to a lower dose, slow escalation, or consider alternative peptides. Dehydration worsens nausea; ensure adequate fluid intake.

Can genetic predispositions predict my exact semaglutide response and ideal dose?

Genetic variants in GLP-1 and metabolic pathways may help provide context for appetite regulation patterns, but do not predict exact medication response. The Precision Peptide Genetic Test reveals predispositions that support a more informed provider conversation alongside clinical labs and medical history.

How Much Ozempic for Weight Loss: A Comprehensive Guide